高级检索

益生菌联合孟鲁司特在肺炎支原体肺炎合并心肌损伤患儿中的治疗效果

Efficacy of probiotics combined with montelukast in treatment of children with Mycoplasma pneumoniae pneumonia complicated with myocardial injury

    摘要
  • 摘要:
    目的 观察益生菌联合孟鲁司特在肺炎支原体肺炎(MPP)合并心肌损伤患儿中的治疗效果。
    方法 选取102例MPP伴心肌损伤患儿为研究对象, 随机分为对照组和观察组，每组51例。对照组给予孟鲁司特治疗，观察组在对照组基础上给予益生菌制剂治疗。比较2组患儿的临床疗效、症状消退时间、住院时间、心肌损伤指标、炎症细胞因子、肠道菌群水平及不良反应发生率。
    结果 观察组总有效率为92.16%, 高于对照组的76.47%, 差异有统计学意义(P < 0.05)。观察组的发热、咳嗽、气促、胸闷胸痛症状消退时间及住院时间短于对照组，差异有统计学意义(P < 0.05)。治疗后，观察组心肌肌钙蛋白T(cTnT)、B型钠尿肽(BNP)、肌红蛋白(Mb)、心肌型脂肪酸结合蛋白(H-FABP)水平低于对照组，差异有统计学意义(P < 0.05); 观察组白细胞介素-1受体1 (IL-1R1)、γ-干扰素(γ-IFN)、高迁移率族蛋白1(HMGB1)水平低于对照组，差异有统计学意义(P < 0.05); 观察组双歧杆菌、嗜酸乳杆菌、粪肠球菌、蜡样芽孢杆菌数量多于对照组，而大肠杆菌、沙门氏菌数量少于对照组，差异有统计学意义(P < 0.05)。2组不良反应发生率比较，差异无统计学意义(P>0.05)。
    结论 益生菌联合孟鲁司特应用于MPP伴心肌损伤患儿的疗效良好，可缩短其症状消退时间和住院时间，改善患儿心肌损伤指标，抑制炎症细胞因子水平，调整肠道菌群紊乱结构，安全性较好。

     

    Abstract:
    Objective To observe the therapeutic effect of probiotics combined with montelukast in children with Mycoplasma pneumoniae pneumonia (MPP) complicated with myocardial injury.
    Methods A total of 102 children with MPP and myocardial injury were selected as the study objects, and were randomly divided into control group and observation group, with 51 cases in each group. The control group was treated with montelukast, and the observation group was treated with probiotics based on the control group. The clinical efficacy, symptom resolution time, hospital stay, myocardial injury index, inflammatory cytokines, intestinal flora level and incidence of adverse reactions were compared between the two groups.
    Results The total effective rate of the observation group was 92.16%, which was significantly higher than 76.47% of the control group (P < 0.05). The disappearance time of symptoms of fever, cough, shortness of breath, chest tightness and chest pain and hospital stay in the observation group were significantly shorter than those in the control group (P < 0.05). After treatment, the levels of cardiac troponin T (cTnT), B-type natriuretic peptide (BNP), myoglobin (Mb) and cardiac fatty acid binding protein (H-FABP) in the observation group were significantly lower than those in the control group(P < 0.05); the levels of interleukin-1 receptor 1(IL-1R1), gamma-interferon (γ-IFN) and high mobility group protein 1(HMGB1) in the observation group were significantly lower than those inthe control group (P < 0.05); the number of Bifidobacteria, Lactobacillus acidophilus, Enterococcus faecalis and Bacillus cereus in the observation group were significantly higher than the control group, while the number of Escherichia coli and Salmonella were significantly lower than those in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).
    Conclusion Probiotics combined with montelukast have good efficacy in MPP children with myocardial injury, which can shorten the time of symptom resolution and hospital stay, improve the indexes of myocardial injury in children, inhibit the level of inflammatory cytokines, adjust the structure of intestinal flora disorder, and have good safety.

     

    • HTML全文
    • 参考文献(21)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回